- glossary ON | OFF
- |
-
text zoom - |
- e-mail page
- |
- print page
Focus on HER3 in ovarian cancer
Slide Deck
View the HER3 slide deck
HER3 interacts with other HER family receptors in ovarian cancer
Preclinical research suggests the presence of HER3 interactions specific to ovarian cancer. These include4:
- Prolonged activation of the MAPK survival pathway in response to activation of both HER3 and HER4
- Activation by the ligand heregulin independent of HER2 and HER4
The clinical significance of these findings is unclear.
